2025-06-05-Jefferies-沛妙医疗（PEN）_纽约心态_对Thunderbolt持乐观态度；在静脉血栓栓塞症（VTE）领域获取市场份额_7页_103kb

Penumbra Inc. (PEN) Equity Research Summary

Company Overview

Penumbra is a medical device company focused on neurovascular and vascular interventions, serving professionals like interventional neuroradiologists and cardiologists. Headquartered in Alameda, California, the company develops, manufactures, and commercializes devices for stroke and vascular disease treatments.

Investment Recommendation

Jefferies Equity Research assigns a "Buy" rating with a $325 price target, which is a 27% upside from the prior close of $255.33. Analysts are optimistic about Penumbra's near-term opportunities, including the upcoming Thunderbolt CAVT product launch, its neuro business growth, and continued share gains in venous thromboembolism (VTE), particularly pulmonary embolism (PE). The company has a strong profitability trajectory, with a 1Q GM of 66.6% and an adjusted OM of 12.4%, driving by favorable product mix and efficiency. The valuation is based on an 8x 2026 revenue multiple, while risks include regulatory delays, increased competition, COVID disruptions, macro headwinds, and reimbursement changes.

Neuro Business and VTE Strategy

PEN expects to maintain leadership in mechanical thrombectomy for stroke, with a >50% market share, supported by its modulating aspiration technology. The Thunderbolt product is expected to drive share growth, with an FDA submission in late March and potential trial data before year-end 2025. In VTE, PEN achieved ~30% PE share with a target of 50% and >50% DVT share, underpinned by strong y/y growth (40%+ in Q1) and the STORM-PE trial likely read out in 2026, which could accelerate market penetration.

Financial Performance and Outlook

Penumbra showed robust 1Q profitability with a GM of 66.6% and OM of 12.4%, improving significantly from prior year. FY25 GM is expected to expand at least 100 bps to over 67%, with OM in the 13-14% range. 2Q guidance anticipates GM to be similar or slightly lower due to manufacturing investments, but q/q increases are expected in 2H 2025. By 2026, gross margin targets exceed 70%.

Valuation and Risks

The $325 target is based on $1.57B in 2026 sales, with risks including regulatory hurdles, competitive threats, and macroeconomic factors. Penumbra's valuation methodology incorporates growth, revenue streams, and discounted cash flow analyses, but emphasizes the need for favorable outcomes from clinical trials and market penetration efforts.